Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $99.6 million.

  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents fell 15.31% to $169.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 15.31%. This contributed to the annual value of $99.6 million for FY2024, which is 3.14% down from last year.
  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents amounted to $99.6 million in FY2024, which was down 3.14% from $102.8 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash & Equivalents peaked at $155.6 million during FY2022, and registered a low of $42.3 million during FY2021.
  • Its 3-year average for Cash & Equivalents is $119.3 million, with a median of $102.8 million in 2023.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Cash & Equivalents soared by 267.81% in 2022, and later slumped by 33.91% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash & Equivalents stood at $45.9 million in 2020, then fell by 7.84% to $42.3 million in 2021, then skyrocketed by 267.81% to $155.6 million in 2022, then crashed by 33.91% to $102.8 million in 2023, then decreased by 3.14% to $99.6 million in 2024.